{"id":1781,"date":"2026-05-06T21:00:00","date_gmt":"2026-05-06T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=bc38fddf35b14e9ef16ef2e5ff2fe8f2"},"modified":"2026-05-06T21:00:00","modified_gmt":"2026-05-06T19:00:00","slug":"securities-fraud-investigation-into-genedx-holdings-corp-wgs-announced-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-a-leading-securities-fraud","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=1781","title":{"rendered":"Securities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced \u2013 Shareholders Who Lost Money Urged To Contact\u00a0Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP<\/a>, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx\u00a0Holdings Corp. (\u201cGeneDx\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0WGS<\/a>) investors concerning the Company\u2019s possible violations of the federal securities laws.<\/p><\/a><\/a>

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENEDX HOLDINGS CORP. (WGS), CLICK\u00a0<\/b>HERE<\/b><\/a>\u00a0TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.<\/b><\/p>

What Happened?<\/b><\/p>

On May 4, 2026, after market hours, GeneDx released its first quarter 2026 financial results, revealing earnings per share of -$0.28, and a $57.5 million loss from operations<\/b><\/i>. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint.<\/p>

GeneDx revealed it had \u201clower-than-expected blended average reimbursement rate for exome and genome\u201d and \u201csofter-than-expected performance from [its] noncore business lines\u201d including Fabric Genomics.<\/p>

The Company also took a $31.3 million write-down\u00a0<\/b><\/i>related to the goodwill and intangible assets of its Fabric Genomics reporting unit, \u201cprimarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.\u201d<\/p>

On this news, GeneDx\u2019s stock price fell $33.42, or 49.2%<\/b><\/i>, to close at $34.51 per share on May 5, 2026, thereby injuring investors.<\/p>

Contact Us To Participate or Learn More:<\/b><\/p>

If you wish to\u202flearn more\u202fabout this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.<\/p>

Charles\u00a0Linehan, Esq.,Glancy Prongay Wolke & Rotter LLP,1925 Century Park East, Suite 2100,Los Angeles California 90067Email: shareholders@glancylaw.com<\/a>Telephone: 310-201-9150 (Toll-Free: 888-773-9224)Visit our website at\u00a0www.glancylaw.com<\/a>.Follow us for updates on LinkedIn<\/a>, Twitter<\/a>, or Facebook<\/a>.<\/p>

Whistleblower Notice<\/b><\/p>

Persons with non-public information regarding GeneDx should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com<\/a>.<\/p>

About Glancy Prongay Wolke & Rotter LLP<\/b><\/p>

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm\u2019s recent successes, GPWR was named one of Law360\u2019s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR\u2019s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR\u2019s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal<\/i>, The Financial Times<\/i>, Bloomberg Businessweek<\/i>, Reuters<\/i>, the Associated Press<\/i>, Barron\u2019s<\/i>, Investor\u2019s Business Daily<\/i>, Forbes<\/i>, and Money<\/i>. Prior results do not guarantee a similar outcome.<\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

Glancy Prongay Wolke & Rotter LLP,1925 Century Park East, Suite 2100,Los Angeles, CA 90067Charles Linehan<\/b>Email: shareholders@glancylaw.com<\/a>Telephone: 310-201-9150Toll-Free: 888-773-9224Visit our website at:\u00a0www.glancylaw.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx\u00a0Holdings Corp. (\u201cGeneDx\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0WGS) inv…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1781","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/1781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1781"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/1781\/revisions"}],"predecessor-version":[{"id":1782,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/1781\/revisions\/1782"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}